Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.48 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6205691 | 0.86 | KCNH2 (0.51) | KCNH2PRMT5WDR77CYP1A2CYP3A4 | |
| SCHEMBL7005719 | 0.81 | CYP3A4 (0.52) | CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4864558 | 0.80 | CYP3A4 (0.67) | CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4033617 | 0.77 | CYP3A4 (0.55) | CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6207329 | 0.77 | KCNH2 (0.49) | KCNH2PRMT5WDR77CYP1A2CYP3A4 | |
| SCHEMBL5228562 | 0.77 | CYP3A4 (0.48) | CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5223317 | 0.73 | KCNH2 (0.47) | KCNH2PRMT5WDR77CYP3A4 | |
| SCHEMBL5228642 | 0.73 | CYP1A2 (0.47) | CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5965111 | 0.73 | CYP3A4 (0.53) | CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5901541 | 0.73 | CYP3A4 (0.53) | CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1806346-A1 | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors | CV THERAPEUTICS, INC. (US) | 2007-07-11 | — | — | EP | disclosed |
| EP-1567525-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004052887-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2004-06-24 | — | — | WO | disclosed |